Telix Pharmaceuticals Aktie

Kaufen

Verkaufen

9,00 EUR -0,35 EUR -3,74 %

08:01:45

FSE

10,66 USD -0,01 USD -0,05 %

21:59:53

BTT

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Div. Rendite0,00%

WKNA40FCQ

ISINUS87961M1053

SymbolTLX

Telix Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

08.01.26PR NewswireTelix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

05.01.26PR NewswireDEADLINE ALERT for FUN, TLX, LRN, PRMB: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

05.01.26PR NewswireTELIX PHARMACEUTICALS (NASDAQ: TLX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by January 9, 2026

23.12.25PR NewswireTelix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

21.12.25PR NewswirePrecision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

15.12.25PR NewswireNASDAQ: TLX INVESTOR ALERT: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors of a January 9, 2026 Deadline

10.12.25PR NewswireTelix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

09.12.25PR NewswireCLASS ACTION NOTICE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action

07.12.25PR NewswireProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

02.12.25PR NewswireATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit

28.11.25PR NewswireTelix Pharmaceuticals Ltd. Shareholders with Large Losses Should Contact Robbins LLP for Information About the TLX Class Action

21.11.25PR NewswireTelix Opens TMS Yokohama in Japan, Commemorative Lecture Held

19.11.25PR NewswireZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

19.11.25PR NewswireBerger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing

18.11.25PR NewswireShareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

14.11.25PR NewswireTLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

12.11.25PR NewswireBerger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing

11.11.25PR NewswireOPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer

11.11.25PR NewswireTLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm

04.11.25PR NewswireRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

23.10.25PR NewswireTLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

22.10.25PR NewswireTelix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

14.10.25PR NewswireTelix Reports US$206M Revenue, FY 2025 Guidance Upgraded

10.10.25PR NewswireRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

01.10.25PR NewswireTelix Announces Record-Breaking Presence at EANM 2025

10.09.25PR NewswireTelix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

03.09.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

27.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

22.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

21.08.25PR NewswireTelix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

16.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

06.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

31.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

30.07.25PR NewswireTelix H1 2025 Results: Investor Webcast Notification

22.07.25PR NewswireTelix Reports $204M Revenue, Up 63% YOY

20.07.25PR NewswireProstatakrebs-PSMA-PET-Bildgebungsmittel Illuccix® in Österreich zugelassen

09.07.25PR NewswireGozellix Receives Permanent HCPCS Code

25.06.25PR NewswireTelix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

13.06.25PR NewswireIlluccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece

05.06.25PR NewswireTelix's Illuccix® PSMA-PET Imaging Agent Approved in Germany

Telix Pharmaceuticals News

Telix Pharmaceuticals News: auf dieser Seite finden Sie alle Telix Pharmaceuticals News und Nachrichten zur Telix Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Telix Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Telix Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.